

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report

(Date of earliest event reported): October 9, 2001

**ARIAD PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in its Charter)

Delaware  
(State or Other Jurisdiction  
of Incorporation)

0-21696  
(Commission File Number)

22-3106987  
(I.R.S. Employer Identification  
No.)

26 LANDSDOWNE STREET  
CAMBRIDGE, MASSACHUSETTS 02139  
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code:  
(617) 494-0400

## **TABLE OF CONTENTS**

[ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.](#)

[ITEM 9. REGULATION FD DISCLOSURE](#)

[SIGNATURES](#)

[EXHIBIT INDEX](#)

[PRESS RELEASE](#)

**ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.**

(c) Exhibits.

99.1 The Registrant's Press Release dated October 9, 2001.

**ITEM 9. REGULATION FD DISCLOSURE**

On October 9, 2001, the Registrant publicly disseminated a Press Release announcing that the Company will present an update of its product development portfolio and business development initiatives at the UBS Warburg Global Life Sciences Conference on Thursday, October 11, 2001.

The information contained in the Press Release dated October 9, 2001 is incorporated herein by reference and attached as Exhibit 99.1 hereto. This information is furnished, and not filed, pursuant to Item 9.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**ARIAD PHARMACEUTICALS, INC.**

By: /s/ Brian A. Lajoie  
Brian A. Lajoie  
Interim Chief Financial Officer

Date: October 9, 2001

EXHIBIT INDEX

Exhibit Number	Description	Sequential Page Number
99.1	The Registrant's Press Release dated October 9, 2001.	4